We are live on ! Find out more
OXFD

Oxford Immunotec Global PLC Ordinary Shares
OXFD

Delisted

OXFD was delisted on the 5th of March, 2021.

86 hedge funds and large institutions have $346M invested in Oxford Immunotec Global PLC Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

40% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 25

7% less funds holding

Funds holding: 9286 (-6)

18% less capital invested

Capital invested by funds: $420M → $346M (-$74.8M)

20% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 20

Holders
86
Holders Change
-6
Holders Change %
-6.52%
% of All Funds
1.87%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
16
Increased
35
Reduced
25
Closed
20
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FLAM
1
First Light Asset Management
Minnesota
$43.2M +$6.07M +396,868 +14%
Invesco
2
Invesco
Georgia
$36.9M -$340K -22,204 -0.8%
PC
3
Polar Capital
United Kingdom
$35.3M +$159K +10,412 +0.4%
CCM
4
Consonance Capital Management
New York
$32.2M -$4.06M -265,260 -10%
RG
5
Redmile Group
California
$24.7M -$3.14M -204,990 -10%
Alyeska Investment Group
6
Alyeska Investment Group
Illinois
$22.7M +$14.2M +928,998 +129%
Millennium Management
7
Millennium Management
New York
$15.4M +$15.5M +1,010,462 +939%
GPGA
8
Grandeur Peak Global Advisors
Utah
$10.9M +$2.46M +160,904 +25%
GIM
9
Granahan Investment Management
Massachusetts
$10.7M -$829K -54,200 -7%
ECM
10
Endurant Capital Management
California
$8.66M +$8.05M +526,643 +513%
BG
11
Bellevue Group
Switzerland
$7.96M +$802K +52,453 +10%
Renaissance Technologies
12
Renaissance Technologies
New York
$7.65M +$4.04M +263,900 +90%
Morgan Stanley
13
Morgan Stanley
New York
$6.99M +$2.7M +176,377 +53%
SM
14
Senvest Management
New York
$6.75M +$1.84M +120,329 +32%
CAM
15
Cortina Asset Management
Wisconsin
$6.09M -$1.62M -105,833 -19%
Deutsche Bank
16
Deutsche Bank
Germany
$4.65M +$2.59M +169,031 +100%
Citadel Advisors
17
Citadel Advisors
Florida
$4.49M +$3.64M +238,001 +270%
PCM
18
Penn Capital Management
Pennsylvania
$3.74M +$71.1K +4,648 +2%
Northern Trust
19
Northern Trust
Illinois
$3.63M -$534K -34,888 -12%
FI
20
Fosun International
China
$3.27M
SCM
21
Stonepine Capital Management
Oregon
$3.14M +$1.54M +100,676 +79%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$2.52M -$69.9K -4,570 -2%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$2.52M -$388K -25,362 -12%
MAM
24
Martingale Asset Management
Massachusetts
$2.29M +$18.4K +1,200 +0.7%
USAA
25
United Services Automobile Association
Texas
$2.28M -$175K -11,445 -6%

OXFD Hedge Fund Activity: Q2 2019 in Review

86 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q2 2019, worth a combined $346M — down 18% from $420M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of OXFD and 16 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 35 added.

The largest buyer was Millennium Management, adding an estimated $15.5M. The largest seller was BlackRock, cutting an estimated $18.6M.

  • 86 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q2 2019, down from 92 in Q1 2019.
  • Funds reported $346M of Oxford Immunotec Global PLC Ordinary Shares stock for Q2 2019, down 18% quarter-over-quarter.
  • 16 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q2 2019 and 20 closed out, a net change of -4 holders.
  • The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q2 2019 was Millennium Management, an estimated $15.5M added.
  • The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q2 2019 was BlackRock, an estimated $18.6M sold.

Based on aggregated 13F filings for Q2 2019.